Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995930 | 1.00 | CA2 (0.33) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5995609 | 0.79 | CHRNB2 (0.32) | CA2CA12CA1CA9CHRNB2 | |
| SCHEMBL5995611 | 0.79 | CHRNB2 (0.32) | CA2CA12CA1CA9CHRNB2 | |
| SCHEMBL5996015 | 0.72 | TSHR (0.35) | — | |
| SCHEMBL3628581 | 0.71 | PHGDH (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5995283 | 0.71 | CA2 (0.35) | CA2CA12CA1CA9CHKA | |
| SCHEMBL25703358 | 0.71 | CA2 (0.45) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5930263 | 0.70 | CA2 (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL14134976 | 0.70 | CA2 (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL14289079 | 0.65 | CA2 (0.34) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2006-10-05 | — | — | US | claimed |
| EP-0973780-B1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO -3-(METHYLHYDRAZONO) METHYL-CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GMBH (AT) | 2003-07-02 | — | — | EP | claimed |
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2003-06-19 | — | — | US | claimed |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2002-08-22 | — | — | US | claimed |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2002-07-11 | — | — | US | claimed |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2006-10-05 | — | — | US | disclosed |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2004-07-08 | — | — | US | disclosed |
| US-6693095-B2 | 7-(((5-AMINO-1,2,4-THIADIAZOL-3-YL)-(Z)-(FLUORMETHOXYIMINO) -ACETYL)AMINO)-3(E)-((IMINO-1-PIPERAZINYLMETHYL)-METHYLHYDRAZONO)METHYL-3 -CEPHEM-4-CARBOXYLIC ACID TRIHYDROCHLORIDE FOR EXAMPLE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2004-02-17 | — | — | US | disclosed |
| EP-0973780-B1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO -3-(METHYLHYDRAZONO) METHYL-CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GMBH (AT) | 2003-07-02 | — | — | EP | disclosed |
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2003-06-19 | — | — | US | disclosed |
| EP-1300408-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono)methyl-cephalosporins and intermediates | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2003-04-09 | — | — | EP | disclosed |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2002-08-22 | — | — | US | disclosed |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA2 4134/4885CA12 4665/4885CA1 4759/4885 |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA2 4134/4885CA12 4665/4885CA1 4759/4885 |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA2 4134/4885CA12 4665/4885CA1 4759/4885 |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, PRMT7 | CA2 4341/4885CA12 4718/4885CA1 4858/4885 |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA2 4134/4885CA12 4665/4885CA1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.